Trial Profile
A Phase 1/2 Multicenter Study of BMS-986012 in Subjects With Relapsed/Refractory Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs BMS 986012 (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; First in man
- Sponsors Bristol-Myers Squibb
- 06 Feb 2023 Status changed from active, no longer recruiting to completed.
- 29 Jan 2023 This trial has been completed in Netherlands, according to European Clinical Trials Database record
- 19 Jan 2023 This trial has been completed in Belgium (End Date: 21 Dec 2022) according to European Clinical Trials Database record.